Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units

[1]  K. Y. Tsang,et al.  Synthesis and biological evaluation of sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. , 2017, Bioorganic & medicinal chemistry.

[2]  Christopher B. Cooper,et al.  6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis , 2017, ACS medicinal chemistry letters.

[3]  K. Dooley,et al.  Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug , 2014, The Journal of antimicrobial chemotherapy.

[4]  N. Dahiya,et al.  Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. , 2014, Tuberculosis.

[5]  J. Violin,et al.  Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. , 2013, Journal of medicinal chemistry.

[6]  Weida Tong,et al.  High lipophilicity and high daily dose of oral medications are associated with significant risk for drug‐induced liver injury , 2013, Hepatology.

[7]  K. Andries,et al.  Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance , 2012, Antimicrobial Agents and Chemotherapy.

[8]  K. Andries,et al.  Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207. , 2011, Future medicinal chemistry.

[9]  W. Denny,et al.  Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). , 2010, Journal of medicinal chemistry.

[10]  C. Sreeramareddy,et al.  Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature , 2009, BMC infectious diseases.

[11]  G. Booker,et al.  Sequential and selective Buchwald-Hartwig amination reactions for the controlled functionalization of 6-bromo-2-chloroquinoline: synthesis of ligands for the Tec Src homology 3 domain. , 2008, The Journal of organic chemistry.

[12]  Dirk Bald,et al.  Diarylquinolines target subunit c of mycobacterial ATP synthase. , 2007, Nature chemical biology.

[13]  D. Connolly,et al.  Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. , 2007, Journal of medicinal chemistry.

[14]  S. Franzblau,et al.  Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating Mycobacterium tuberculosis , 2007, Antimicrobial Agents and Chemotherapy.

[15]  S. Franzblau,et al.  In Vitro and In Vivo Activities of Macrolide Derivatives against Mycobacterium tuberculosis , 2005, Antimicrobial Agents and Chemotherapy.

[16]  L. Collins,et al.  Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium , 1997, Antimicrobial agents and chemotherapy.